PL406033A1 - Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny - Google Patents

Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny

Info

Publication number
PL406033A1
PL406033A1 PL406033A PL40603313A PL406033A1 PL 406033 A1 PL406033 A1 PL 406033A1 PL 406033 A PL406033 A PL 406033A PL 40603313 A PL40603313 A PL 40603313A PL 406033 A1 PL406033 A1 PL 406033A1
Authority
PL
Poland
Prior art keywords
diagnosing
thyroid
carcinoma
mir
patient
Prior art date
Application number
PL406033A
Other languages
English (en)
Inventor
Krystian Jażdżewski
Anna Wójcicka
Anna Kubiak
Wojciech Gierlikowski
Monika Maciąg
Monika Kolanowska
Agnieszka Czajka
Marta Kotlarek
Michał Świerniak
Original Assignee
Warszawski Uniwersytet Medyczny
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warszawski Uniwersytet Medyczny filed Critical Warszawski Uniwersytet Medyczny
Priority to PL406033A priority Critical patent/PL406033A1/pl
Priority to PCT/IB2014/066057 priority patent/WO2015071876A2/en
Publication of PL406033A1 publication Critical patent/PL406033A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Przedmiotem wynalazku jest sposób diagnozowania zmiany chorobowej, takiej jak nowotwór i/lub zmiana łagodna tarczycy u pacjenta, który to sposób obejmuje: - dostarczanie pochodzącej od pacjenta próbki biologicznej, - określanie ilości jednego lub więcej mikroRNA wybranego z grupy obejmującej miR-146b-5p, miR-146b-3p, miR-221-5p, miR-221-3p, miR-222-5p, miR-222-3p, miR-181a-5p i miR-182-5p w próbce biologicznej, - porównywanie ekspresji mikroRNA z poziomem ekspresji mikroRNA w grupie kontrolnej, - diagnozowanie wystąpienia nowotworu /i/lub zmiany łagodnej u pacjenta, jeśli poziom ekspresji mikroRNA w próbce biologicznej jest zmieniony względem poziomu ekspresji obserwowanej w próbkach płynów biologicznych w grupie kontrolnej. Przedmiotem wynalazku jest także zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie tarczycy oraz zestaw do diagnozowania zmiany chorobowej.
PL406033A 2013-11-14 2013-11-14 Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny PL406033A1 (pl)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PL406033A PL406033A1 (pl) 2013-11-14 2013-11-14 Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny
PCT/IB2014/066057 WO2015071876A2 (en) 2013-11-14 2014-11-14 Use of microrna markers for diagnosis of thyroid tumors and a diagnostic panel containing such markers.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL406033A PL406033A1 (pl) 2013-11-14 2013-11-14 Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny

Publications (1)

Publication Number Publication Date
PL406033A1 true PL406033A1 (pl) 2015-05-25

Family

ID=53058217

Family Applications (1)

Application Number Title Priority Date Filing Date
PL406033A PL406033A1 (pl) 2013-11-14 2013-11-14 Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny

Country Status (2)

Country Link
PL (1) PL406033A1 (pl)
WO (1) WO2015071876A2 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4303323A1 (en) 2022-07-05 2024-01-10 Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Oddzial w Gliwicach A method differentiating benign and malignant tyroid nodules

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008058018A2 (en) 2006-11-02 2008-05-15 Mayo Foundation For Medical Education And Research Predicting cancer outcome
AU2009253675A1 (en) 2008-05-28 2009-12-03 Genomedx Biosciences, Inc. Systems and methods for expression-based discrimination of distinct clinical disease states in prostate cancer
US10407731B2 (en) 2008-05-30 2019-09-10 Mayo Foundation For Medical Education And Research Biomarker panels for predicting prostate cancer outcomes
US9495515B1 (en) 2009-12-09 2016-11-15 Veracyte, Inc. Algorithms for disease diagnostics
US10236078B2 (en) 2008-11-17 2019-03-19 Veracyte, Inc. Methods for processing or analyzing a sample of thyroid tissue
US9074258B2 (en) 2009-03-04 2015-07-07 Genomedx Biosciences Inc. Compositions and methods for classifying thyroid nodule disease
EP3360978A3 (en) 2009-05-07 2018-09-26 Veracyte, Inc. Methods for diagnosis of thyroid conditions
US10446272B2 (en) 2009-12-09 2019-10-15 Veracyte, Inc. Methods and compositions for classification of samples
US20130267443A1 (en) 2010-11-19 2013-10-10 The Regents Of The University Of Michigan ncRNA AND USES THEREOF
US10513737B2 (en) 2011-12-13 2019-12-24 Decipher Biosciences, Inc. Cancer diagnostics using non-coding transcripts
EP2885640B1 (en) 2012-08-16 2018-07-18 Genomedx Biosciences, Inc. Prostate cancer prognostics using biomarkers
US11976329B2 (en) 2013-03-15 2024-05-07 Veracyte, Inc. Methods and systems for detecting usual interstitial pneumonia
US12297505B2 (en) 2014-07-14 2025-05-13 Veracyte, Inc. Algorithms for disease diagnostics
US20170335396A1 (en) 2014-11-05 2017-11-23 Veracyte, Inc. Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data
EP3504348B1 (en) 2016-08-24 2022-12-14 Decipher Biosciences, Inc. Use of genomic signatures to predict responsiveness of patients with prostate cancer to post-operative radiation therapy
WO2018132916A1 (en) 2017-01-20 2018-07-26 Genomedx Biosciences, Inc. Molecular subtyping, prognosis, and treatment of bladder cancer
CA3055925A1 (en) 2017-03-09 2018-09-13 Decipher Biosciences, Inc. Subtyping prostate cancer to predict response to hormone therapy
AU2018266733A1 (en) 2017-05-12 2020-01-16 Veracyte, Inc. Genetic signatures to predict prostate cancer metastasis and identify tumor aggressiveness
US11217329B1 (en) 2017-06-23 2022-01-04 Veracyte, Inc. Methods and systems for determining biological sample integrity
WO2019028285A2 (en) 2017-08-04 2019-02-07 Genomedx, Inc. USE OF SPECIFIC GENE EXPRESSION OF IMMUNE CELLS FOR THE PROGNOSIS OF PROSTATE CANCER AND THE PREDICTION OF SENSITIVITY TO RADIOTHERAPY
KR102649965B1 (ko) * 2019-01-11 2024-03-22 연세대학교 산학협력단 갑상선 수질암 표적용 조성물
RU2705110C1 (ru) * 2019-04-10 2019-11-06 Государственное бюджетное учреждение здравоохранения "Краевая клиническая больница N2" Министерства здравоохранения Краснодарского края Способ дифференциальной диагностики новообразований щитовидной железы
CN111286538B (zh) * 2020-02-13 2023-04-07 朱伟 一种与泛肿瘤辅助诊断相关的循环miRNA和癌胚miRNA标志物及其应用
CN114196759B (zh) * 2021-12-31 2023-10-20 深圳市海普洛斯生物科技有限公司 一种尿液样本的胰腺癌生物标志物及其应用
CN116769922B (zh) * 2023-08-24 2023-11-24 四川大学华西医院 检测循环sEV RNA试剂的用途、试剂盒和诊断系统
CN118326047A (zh) * 2024-06-14 2024-07-12 润安医学科技(苏州)有限公司 一组microRNA标志物在甲状腺结节良恶性鉴别中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004052184A2 (en) 2002-12-12 2004-06-24 Oncotech, Inc. Genes related to sensitivity and resistance to chemotherapeutic drug treatment
WO2006060742A2 (en) 2004-12-02 2006-06-08 Oncotech, Inc. Reagents and methods for predicting drug resistance
ES2553442T3 (es) 2006-01-05 2015-12-09 The Ohio State University Research Foundation Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
US20080076674A1 (en) 2006-07-06 2008-03-27 Thomas Litman Novel oligonucleotide compositions and probe sequences useful for detection and analysis of non coding RNAs associated with cancer
EP2090665A2 (en) 2006-10-20 2009-08-19 Exiqon A/S Novel human microRNAs associated with cancer
US20090099034A1 (en) 2007-06-07 2009-04-16 Wisconsin Alumni Research Foundation Reagents and Methods for miRNA Expression Analysis and Identification of Cancer Biomarkers
CA2676113C (en) 2007-07-25 2014-07-08 University Of Louisville Research Foundation, Inc. Exosome-associated microrna as a diagnostic marker
WO2009080437A1 (en) 2007-12-21 2009-07-02 Exiqon A/S Micro-rna based drug resistance analysis method
US20110160290A1 (en) 2008-05-21 2011-06-30 Muneesh Tewari Use of extracellular rna to measure disease
WO2010145035A1 (en) 2009-06-19 2010-12-23 Siu K W Michael Renal cell carcinoma biomarkers
EP2341145A1 (en) 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
WO2012009499A2 (en) 2010-07-15 2012-01-19 Mayo Foundation For Medical Education And Research Assessing thyroid neoplasms and treating cancer
BR112013012265A2 (pt) * 2010-11-17 2016-08-02 Asuragen Inc mirnas como biomarcadores para distinguir neoplasmas de tireoide benignos de malignos
JP2014511677A (ja) * 2011-03-22 2014-05-19 コーネル・ユニバーシティー 鑑別困難な良性甲状腺病変と悪性甲状腺病変との識別法
EP2505664B1 (en) * 2011-03-30 2014-12-03 Universität Leipzig Method and means for distinguishing malignant from benign tumor samples, in particular in routine air dried fine needle aspiration biopsy (FNAB)
WO2013063544A1 (en) * 2011-10-27 2013-05-02 Asuragen, Inc. Mirnas as diagnostic biomarkers to distinguish benign from malignant thyroid tumors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4303323A1 (en) 2022-07-05 2024-01-10 Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Oddzial w Gliwicach A method differentiating benign and malignant tyroid nodules

Also Published As

Publication number Publication date
WO2015071876A2 (en) 2015-05-21
WO2015071876A3 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
PL406033A1 (pl) Sposób diagnozowania raka brodawkowatego tarczycy, zastosowanie markera mikroRNA do diagnozowania nowotworu tarczycy, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny
PL405648A1 (pl) Sposób diagnozowania raka watrobowokomórkowego, zastosowanie markera mikroRNA do diagnozowania zmiany chorobowej w obrębie wątroby, oceny stopnia zaawansowania choroby oraz oceny podatności pacjenta i/lub choroby na zaproponowane leczenie oraz zawierający takie markery zestaw diagnostyczny
PH12018550037A1 (en) Quencher containing water-soluble polymer-conjugated nanomaterial and use thereof
CL2008001517A1 (es) Dispositivo para determinar el riesgo de progresion de melanoma que comprende oligonucleotidos de uno o mas marcadores de pronostico de melanoma (mpms) escogidos de un grupo de seleccion; procedimiento para determinar la prognosis de melanoma en un paciente; procedimiento para determinar la adecuacion de un paciente de melanoma para un ensayo de droga.
BR112014030750A2 (pt) Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
MX382266B (es) Metodo para el diagnostico, pronostico y tratamiento de la metastasis de cancer de mama.
MY182773A (en) Method for indicating a presence or non-presence of aggressive prostate cancer
BR112015008255A2 (pt) método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
PH12015501868A1 (en) Inhibitors of histone demethylases
MX2015001081A (es) Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
BRPI0901277A2 (pt) aplicador marcador de local de biópsia e método
BR112015012644A2 (pt) método para determinar a necessidade de um paciente com câncer, método de tratamento do câncer, composição farmacêutica, uso de um ácido nucleico ou anticorpo e kit;
MX2023001945A (es) Composiciones y metodos para el cribado de tumores solidos.
ATE554389T1 (de) Apex als marker für lungenkrebs
WO2007146668A3 (en) Use of imp3 as a prognostic marker for cancer
EA201490946A1 (ru) Способ количественной оценки лечения рака
BR112014032728A2 (pt) uso de marcadores no diagnóstico e tratamento de câncer de próstata
WO2009083780A8 (en) Breast cancer expression profiling
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
BR112015029550A2 (pt) Anticorpo anti-vegf e composição farmacêutica para prevenção, diagnóstico ou tratamento de câncer ou doença relacionada à angiogênese contendo o mesmo
ES2570631T3 (es) Procedimiento de determinación de la apolipoproteína AII para el diagnóstico in vitro del cáncer colorrectal
Jiang et al. Node-extranodal soft tissue stage based on extranodal metastasis is associated with poor prognosis of patients with gastric cancer
MY187655A (en) Use of nucleosome-transcription factor complexes for cancer detection